Obesity Drug Coverage Could Boost Spending By $35B Through 2034
Sector Update: Health Care
Pfizer's Bondholders Cheer News of Activist Investor Starboard's $1 Billion Investment
RSV vaccine sales in the US dropped significantly, as the 'most imaginative product' faced a heavy blow from the CDC.
①Independent pharmacists reported that the demand for RSV vaccines in the autumn has decreased by two-thirds compared to a year ago; ②In September last year, an average of approximately 0.44 million people received glaxosmithkline or pfizer's RSV vaccines per week; whereas this September, the average number of people per week is around 0.157 million.
Pfizer CEO's Job Is at Risk. A Shot of Discipline Could Help. -- WSJ
Daily short sale tracking: NVIDIA's short volume increased by 7 million, with a short sale ratio of 8%
NVIDIA(NVDA.US) ranked top of the list had the largest change in short volume (7.95 million shares), and the short volume ratio of Royal Bank of Canada(RY.US) reached 66.32%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
GSK Arexvy Protects From RSV Over Three Full Seasons
glaxosmithkline (GSK.US) claims that the protective effect of the RSV vaccine can last for three quarters.
GlaxoSmithKline (GSK.US) said on Tuesday that its respiratory syncytial virus (RSV) vaccine has protective effects in the three quarters after vaccination.
UK Court Sides With Pfizer, BioNTech in MRNA Patent Case Against CureVac
Guggenheim Adjusts Pfizer Price Target to $36 From $35, Maintains Buy Rating
Market Chatter: Pfizer's Former Executives Pitch Starboard's Turnaround Plans to Board
2 Covered Call Ideas on Pfizer Stock
CFRA Initiates Pfizer(PFE.US) With Hold Rating, Announces Target Price $31
Express News | Pfizer (PFE.N) and the German biotechnology company BioNTech have won a lawsuit in the United Kingdom court, successfully invalidating CureVac's patent on mRNA technology in the COVID-19 vaccine.
Express News | Pfizer, BioNTech Win Bid in UK Court to Invalidate CureVac's Patents Over Mrna Technology in Covid-19 Vaccines
Why Pfizer Will Find It Hard to Appease Its Activist Investor -- WSJ
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
Futu Morning Post | Breaking news! The State Council Information Office will hold a press conference at 10 a.m. today, A-shares will open today; join the call on the Chinese stock market! Citigroup: There is still huge room for growth.
Overseas investors are pouring into Chinese stocks, with related funds attracting billions of dollars to set a new record; senior officials of the Federal Reserve temporarily withhold buying, eye-catching non-farm payroll data: overall risk balance slightly leaning towards labor market facing headwinds.
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Pfizer Hold Rating: Balancing Valuation Concerns and Growth Challenges